Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 25, 2026

2 ETFs to Buy With $100 and Hold Forever

View original at finance.yahoo.com
2 ETFs to Buy With $100 and Hold Forever The stock market has already taken investors for a ride in 2026. After a relatively calm first two months of the year, the S&P 500 fell 9% only to turn around and bounce 12% higher off the lows…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Companies that grow steadily over time usually perform the best, better than high-growth speculative plays.

    60% confidence
  • VTI covers the entire U.S. equity market and makes sense as a core portfolio position.

    60% confidence
  • SCHD has a year-to-date return of 12.8%, the best among U.S. dividend ETFs.

    60% confidence
  • Investing in undervalued companies provides above-average returns over the long term if that value is unlocked, and value stocks also provide downside protection in falling markets.

    60% confidence
  • SCHD is one of the most popular dividend ETFs.

    60% confidence
  • The Indispensable Monopoly company provides the critical technology that both Nvidia and Intel need.

    60% confidence
  • AI could create the world's first trillionaire.

    60% confidence
  • Adding SCHD around a core VTI position adds an element of income growth and durability that can enhance long-term total returns.

    60% confidence
  • SCHD's strategy targets stocks that represent the best combination of balance sheet quality, dividend growth, and high yield.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com